Ned Pagliarulo

Lead Editor at BioPharma Dive

Lead editor @BioPharmaDive

Featured in: Favicon

biopharmadive.com Favicon

utilitydive.com Favicon

healthcaredive.com Favicon

fooddive.com Favicon

supplychaindive.com Favicon

ciodive.com Favicon

k12dive.com Favicon

medtechdive.com Favicon

cfodive.com Favicon

industrydive.com + 8 more

Articles

J&J keeps forecasts steady as pharma confronts tariff threat

1 week ago | biopharmadive.com | Ned Pagliarulo

Johnson & Johnson is confident it can manage the impact of tariffs on its pharmaceuticals and medical device businesses this year, announcing Tuesday that it will maintain its financial forecast for the year while raising its sales guidance. J&J, which is the first large drugmaker to report results for the first quarter, expects adjusted earnings per share of $10.60 for 2025.
US launches probe that could set stage for pharma tariffs

1 week ago | healthcaredive.com | Ned Pagliarulo |Susanna Vogel

First published on Listen to the article 3 minThe Trump administration is investigating the effects of pharmaceutical imports on national security, disclosing Monday a probe that is likely to lay the foundation for sector-wide tariffs in the near future. The investigation, which was announced in a federal notice posted online, appears to be wide-ranging, covering branded and generic medicines, as well the active drug ingredients they contain.
US launches probe that could set stage for pharma tariffs

1 week ago | biopharmadive.com | Ned Pagliarulo

This audio is auto-generated. Please let us know if you have feedback. The Trump administration is investigating the effects of pharmaceutical imports on national security, disclosing Monday a probe that is likely to lay the foundation for sector-wide tariffs in the near future. The investigation, which was announced in a federal notice posted online, appears to be wide-ranging, covering branded and generic medicines, as well the active drug ingredients they contain.
Pharma bosses face down investor angst on tariffs, HHS chaos

1 week ago | medtechdive.com | Ned Pagliarulo

This audio is auto-generated. Please let us know if you have feedback. Pharmaceutical executives are likely to get asked many variations on the same few questions this earnings season as Wall Street seeks answers on how well their businesses will weather the storms now damaging the sector. President Donald Trump has roiled global markets by imposing, and then pausing, steep tariffs on U.S. imports.
US launches probe that could set stage for pharma tariffs

1 week ago | flipboard.com | Ned Pagliarulo

US launches probe that could set stage for pharma tariffsThe Trump administration is investigating the effects of pharmaceutical imports on national security, disclosing Monday a probe that is likely to lay …
Pharma bosses face down investor angst on tariffs, HHS chaos

1 week ago | biopharmadive.com | Ned Pagliarulo

Pharmaceutical executives are likely to get asked many variations on the same few questions this earnings season as Wall Street seeks answers on how well their businesses will weather the storms now damaging the sector. President Donald Trump has roiled global markets by imposing, and then pausing, steep tariffs on U.S. imports.
FDA plans to phase out animal testing for some drugs

1 week ago | biopharmadive.com | Ned Pagliarulo

The Food and Drug Administration aims to phase out animal toxicology testing for experimental drugs, announcing Thursday a plan to reduce, revise or replace such requirements in favor of newer methods that are more “human relevant.” The agency’s plan outlines several steps by which it intends to move away from considering animal testing the default approach, including by encouraging drugmakers to adopt other methods, like “organ-on-a-chip” systems or computational modeling.
US risks losing biotech edge to China, report warns

2 weeks ago | pharmavoice.com | Ned Pagliarulo

This audio is auto-generated. Please let us know if you have feedback. The U.S. risks losing a once-decisive edge over China in biotechnology unless the federal government prioritizes the sector’s advancement with new funding and policies, a bipartisan commission warned in a report issued Tuesday. At minimum, the commission wrote, the U.S. should invest at least $15 billion over the next five years to strengthen the country’s biotech capabilities.
US risks losing biotech edge to China, report warns

2 weeks ago | biopharmadive.com | Ned Pagliarulo

The U.S. risks losing a once-decisive edge over China in biotechnology unless the federal government prioritizes the sector’s advancement with new funding and policies, a bipartisan commission warned in a report issued Tuesday. At minimum, the commission wrote, the U.S. should invest at least $15 billion over the next five years to strengthen the country’s biotech capabilities.
RFK Jr. won’t appear before Senate panel this week

2 weeks ago | medtechdive.com | Ned Pagliarulo

A Senate committee hearing involving Health and Human Services Secretary Robert F. Kennedy Jr. won't happen this week as initially proposed by the panel's leading lawmakers, who are seeking answers on the deep-cutting restructuring of the health department that Kennedy ordered last month. Sens.